SPDR S&P BIOTECH ETF (XBI)
| Assets | $6.21B |
| Expense Ratio | 0.35% |
| PE Ratio | n/a |
| Shares Out | 69.05M |
| Dividend (ttm) | $0.13 |
| Dividend Yield | 0.14% |
| Ex-Dividend Date | Sep 23, 2024 |
| Payout Ratio | n/a |
| 1-Year Return | +5.53% |
| Volume | 9,937,607 |
| Open | 89.37 |
| Previous Close | 89.81 |
| Day's Range | 89.34 - 91.96 |
| 52-Week Low | 81.14 |
| 52-Week High | 105.47 |
| Beta | 0.92 |
| Holdings | 147 |
| Inception Date | Jan 31, 2006 |
About XBI
Fund Home PageThe SPDR S&P BIOTECH ETF (XBI) is an exchange-traded fund that is based on the S&P Biotechnology Select Industry index. The fund tracks an equal-weighted index of US biotechnology stocks. XBI was launched on Jan 31, 2006 and is issued by State Street.
Top 10 Holdings
28.12% of assets| Name | Symbol | Weight |
|---|---|---|
| Natera, Inc. | NTRA | 3.48% |
| Neurocrine Biosciences, Inc. | NBIX | 3.07% |
| Gilead Sciences, Inc. | GILD | 3.06% |
| United Therapeutics Corporation | UTHR | 2.96% |
| Incyte Corporation | INCY | 2.94% |
| Sarepta Therapeutics, Inc. | SRPT | 2.67% |
| Insmed Incorporated | INSM | 2.59% |
| Alnylam Pharmaceuticals, Inc. | ALNY | 2.51% |
| AbbVie Inc. | ABBV | 2.46% |
| Exact Sciences Corporation | EXAS | 2.38% |
Dividends
| Ex-Dividend | Amount | Pay Date |
|---|---|---|
| Sep 23, 2024 | $0.015 | Sep 25, 2024 |
| Jun 24, 2024 | $0.115 | Jun 26, 2024 |
| Dec 18, 2023 | $0.014 | Dec 21, 2023 |
| Jun 20, 2023 | $0.003 | Jun 23, 2023 |
| Mar 22, 2021 | $0.040 | Mar 25, 2021 |
| Dec 21, 2020 | $0.176 | Dec 24, 2020 |
News
RFK Jr. could prove a surprise boon for stem-cell stocks with pivotal year ahead
Stem-cell research is on the cusp of a breakthrough that could come as soon as 2025, and two biotech companies with promising therapies stand to gain, according to a new report from Maxim Group on Thu...
Finding Winners In Biotech, Probably The Riskiest Sector
Investing in biotech offers high upside but comes with significant risks, especially with volatile stock movements and binary outcomes from clinical trials, says Jonathan Faison. Focus on multi-year c...
Biotech: 3 Reasons The Recent Selloff Is A Buying Opportunity For XBI (Upgrade)
Biotech had its worst weekly performance since 2020 last week, driven by the post-election rally fizzling and fears surrounding RFK Jr.'s potential impact on the FDA. Concerns about Mr. Kennedy leadin...
Trade Tracker: Joe Terranova sells Amgen and buys XBI
Joe Terranova, senior managing director for Virtus Investment Partners, joins CNBC's 'Halftime Report' to discuss his latest portfolio moves.
XBI: Biotech ETF Is A Must Have
SPDR® S&P Biotech ETF is a well-diversified, low-cost ETF that can be an excellent tool to capitalize on the potential of the biotech stock sector. XBI's performance should be compared with the Russel...
3 Attractive Biotechs With Recent Positives
The small cap biotech sector is trading close to the same levels that it was five years ago. Straight equity holdings have threaded water in this space over the past half decade. However, given the lu...
3 'Repeatable' Biotech Trades
Small-cap biotech stocks have struggled over the past five years, but lower interest rates may boost sentiment and M&A activity, benefiting the sector. One way I have kept my biotech portfolio churnin...
XBI Is Breaking Out And Likely To Outperform In The Near Term (Technical Analysis)
Biotechnology equities have underperformed since late 2020, but recent acquisitions and drug approvals suggest a potential industry revaluation. SPDR S&P Biotech ETF (XBI) offers broad exposure to the...
Biotech Stocks Are Showing Signs of Life. Why the Rally Could Continue.
Thanks to the prospect of lower interest rates, shares of biotech companies have doubled the gains of the broad market over the past few months.
Trade Tracker: Joe Terranova sells the ITA and XBI
Joe Terranova, Senior Managing Director for Virtus Investment Partners, joins CNBC's "Halftime Report" to explain why he's selling these two ETFs.
Biopharmaceutical Stocks: The Next Phase Of The Rally Appears To Be Underway
Stock valuations in the pharmaceutical industry are becoming more attractive for potential mergers due to declining IPO prices. Aging population and prevalence of chronic diseases are driving favorabl...
Biotech stocks will get a tailwind from rate cuts, says Stempoint's Michelle Ross
Michelle Ross, Stempoint Capital, joins 'Closing Bell' to discuss Eli Lilly after the stock saw a slight dip after rallying.
Bond ETFs attract record flows in July as investors position for Fed rate cuts
Hello! Bonds seemed more appealing to ETF investors than ever before in July, based on flow data from State Street. This week's ETF Wrap looks at what's driving investors' appetite for fixed income la...
Final Trades: Amazon, Truist Financial and the XBI
The Investment Committee give you their top stocks to watch for the second half.
Biotech Stocks 2024 Second Half Outlook - Buy Biotechs
Biotech indexes lagged broader market indexes in the first half of 2024, and trade at the same level as in early 2022. Biotech valuations are closely tied to the Fed's interest rate policy and are hig...
M&A Is Back. 4 Stocks That Could Be Targets.
Mergers and acquisitions are on pace for a solid year. Small-cap biotech and tech look interesting.
Final Trades: 2-Year Treasury, Trade Desk, American Express and the XBI
The Investment Committee gives you their top names to watch for the second half.
Homebuilder sentiment tumbles in May
CNBC's Rick Santelli reports on the latest economic data to cross the tape.
For Biotech Stocks To Move Higher, This Must Move Lower
Biotech indexes, represented by IBB and XBI, have been facing pressure since March and trading at valuations seen in April 2020. The key factor influencing biotech valuations, discussed below, is expe...
Why investor appetite for commodity funds picked up despite ETF flows broadly seeing ‘pretty big drop' in April
Hello! This week's ETF Wrap digs into the slump in ETF flows in April and investor positioning around commodities as inflation worries persist.
XBI: The 2 Things Biotech Needs To Move Higher
The biotech sector has experienced significant volatility but has returned around the same as the risk-free return from the 10-Year Treasury over the past year. There are two key items that will deter...
XBI: 3 Reasons To Buy The Pullback And Hold This Biotech ETF Forever
SPDR S&P Biotech ETF offers a buying opportunity after a recent decline and trades close to the 200-day moving average. XBI has a strong long-term track record, providing generous total returns for sh...
Under-the-radar biotech bets
Michelle Ross, StemPoint Capital CIO, joins CNBC's Halftime Report' to discuss her latest biotech pick.
XBI: Biotech Is A Strong Buy As M&A Activity Picks Up (Rating Upgrade)
Shares of biotechnology companies have been lagging behind the S&P 500 Index. This underperformance of XBI relative to the S&P 500, however, has only made the opportunity even more attractive to us. E...